GRTX News and Press, Galera Therapeutics Inc. From 06/29/23

2023-06-29 10:10:59 ET Gainers: RenovoRx ( RNXT ) +37% . Immunome ( IMNM ) +36% .  DermTech ( DMTK ) +15% . Galera Therapeutics ( GRTX ) +9% . Oncolytics Biotech ( ONCY ) +7% . Losers: BioXcel Therapeutics ( BTA...

2023-06-29 08:29:48 ET Eco Wave Power  ( WAVE ) +56% . RenovoRx ( RNXT ) +24% . Kintara Therapeutics ( KTRA ) +22% . Intelligent Living Application  ( ILAG ) +15% . Joby Aviation ( JOBY ) +14% rallies 10% to new 52-week h...

As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of kidney function at month 3 through one year in avasopasem-treated patients Based on ROMAN or...

2023-05-22 17:30:42 ET Gainers: Movella Holdings  ( MVLA ) +14% . Trevi Therapeutics ( TRVI ) +5% . QUALCOMM  ( QCOM ) +5% . Galera Therapeutics ( GRTX ) +4% . LivePerson ( LPSN ) +4% . Losers: Guardant Health (...

2023-05-19 08:20:29 ET Lucy Scientific Discovery  ( LSDI ) +43% . Farfetch Limited ( FTCH ) +22% Q1 earnings call release Greenland Technologies Holding ( GTEC ) +14% Q1 earnings call release Nabriva Therapeutics  ( NBRV ) +11% . G...

MALVERN, Pa., May 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced ...

2023-05-11 09:43:19 ET Galera Therapeutics press release ( NASDAQ: GRTX ): Q1 GAAP EPS of -$0.50 misses by $0.09 . As of March 31, 2023, Galera had cash, cash equivalents and short-term investments of $47.8 million. Galera expects that its existing cash, cash equivalen...

Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering Company expanded commercial team and appointed leading biopharmac...

MALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced ...

Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA)...